Quick answer
A biotech sales pipeline is the set of stages a research-driven deal moves through, from identifying the right lab to a funded purchase, plus the CRM and forecast that track it. Build it around how science actually buys: scientific buyers who evaluate on evidence, a buying group that includes the principal investigator, end-user scientists, procurement and a grant administrator, and timing that follows grant and budget cycles rather than your quarter. The stages that work are not a generic template; they mark real changes in a data-driven buyer's commitment across a long, funding-dependent cycle.
What makes a biotech pipeline different?
Most pipeline advice assumes a buyer who can decide quickly and pay out of a discretionary budget. Biotech breaks both assumptions.
The buyer is a scientist. Principal investigators and the researchers who would use your product evaluate on data and reproducibility, not on a pitch. A stage that reads "sent proposal" means little if the science has not been evaluated. The money is also constrained: purchases follow grant cycles and budget windows, so a deal can be fully qualified on fit and still wait months for funding to open.
That changes what a stage should represent. In a biotech pipeline, a stage is a real shift in a research-driven buyer's commitment: a lab agreed the problem is worth their time, scientists validated the data, procurement confirmed a budget line. For the general principles this builds on, see how to build a sales pipeline and sales pipeline stages. This article adapts them for scientific and lab buyers, the kind described on our biotech go-to-market page.
What stages should a biotech pipeline have?
Start simple and map each stage to buyer commitment, with a clear exit criterion to advance. A workable default for a biotech motion looks like this.
| Stage | What it means | Exit criterion to advance |
|---|---|---|
| Target identified | A specific lab, programme or core facility your product genuinely fits | Named PI or lab lead, confirmed use case |
| Scientific conversation | A researcher has engaged on the technical merits | A real reply or meeting, not just an open |
| Technical evaluation | Data review, demo, sample, or a trial in the lab | Scientists confirm the data holds up |
| Procurement and budget | Lab manager or procurement engaged on purchasing | Budget line identified, process understood |
| Funding confirmed | A grant or budget window is open for the spend | Verbal or written commitment to fund |
| Closed | Order placed | Signed order or PO |
The two stages founders usually miss are technical evaluation and funding confirmed. Skipping the evaluation stage hides the single thing that decides a scientific sale: whether the data convinced the end users. Skipping the funding stage produces a forecast full of deals that are real but cannot close until a grant opens. Keep both explicit.
Who is in the biotech buying group?
A single "contact" almost never represents a biotech opportunity. Gartner has found that the typical B2B buying group involves six to ten decision makers, and life-sciences purchases tend to sit at the higher end because science and procurement both weigh in.
In a typical biotech deal you are tracking at least four roles:
- Principal investigator or lab lead. The champion who judges whether the science is worth pursuing.
- Scientists and end users. The people who evaluate the data and reproducibility and have to want to use the product.
- Procurement or lab manager. Runs purchasing and manages the budget.
- Finance or grant administrator. Controls whether the spend fits inside a grant or budget cycle.
Your pipeline should hold all of them against the account, not a lone lead. Build reporting around accounts and opportunities, because a champion PI with no procurement path and no open funding window is not yet a real deal. That starts with picking a CRM you will keep clean over a long cycle, covered in best CRM for startups; the mechanics of structuring it for the lab committee live in CRM setup for biotech.
How do grant cycles change the pipeline?
Funding timing is the variable that quietly governs a biotech pipeline. A deal can be perfectly qualified on scientific fit and still be unable to move until a grant is awarded or a new budget year opens.
Treat funding as a tracked field, not an afterthought. For each opportunity, capture the likely funding source and when its window opens. That lets you do two things: sequence outreach so you reach a lab when money and need line up, and forecast honestly by separating deals that can close this period from deals that are waiting on funding. A pipeline that ignores this looks either falsely optimistic or mysteriously stalled.
This is also why patience beats pressure here. The right move on a funding-blocked deal is a credible, low-friction touch that keeps you top of mind until the window opens, not a discount to force a quarter.
How do you forecast a long, research-driven pipeline?
Keep it simple and honest. With a handful of deals and cycles measured in months, a complicated weighted model built on thin data invents precision you do not have.
A weighted-by-stage view plus a deal-by-deal read is usually enough, with one biotech-specific overlay: no deal counts as near-term until its funding window is confirmed. Watch stage conversion and where deals stall more than the headline number. If deals pile up at technical evaluation, your data story or targeting is off; if they pile up at funding confirmed, your timing is off. For the broader method, see how to build a sales pipeline, and pair this with a CRM built for it in CRM setup for biotech.
One more foundation worth getting right early is where your deals come from. A pipeline is only as good as the accounts feeding it, which is a targeting and go-to-market question covered in GTM strategy for biotech startups.
Where Enablemnt fits
Everything above is the work: stages that fit scientific buyers, a CRM that holds the full lab committee, funding timing tracked per deal, and a forecast you can trust. You can assemble that over a few messy weeks, or have operators who have built it before stand it up with you.
Enablemnt is your embedded RevOps and outbound team. In a fixed 14-day sprint we build the pipeline this article describes: a data-backed target list of the labs and programmes your product fits, a CRM with stages and fields built for long, funding-dependent cycles, and live outreach written for a data-driven buyer. You own all of it at the end, documented, so you can run it in-house or keep us on to operate it.
If you want a biotech pipeline built right the first time rather than pieced together over a quarter, tell us about your company and we will map your GTM blueprint on a short call.
Follow Enablemnt AI on LinkedInShort, practical posts on GTM, outbound and RevOps for early-stage B2B founders.FollowFrequently asked questions
- What pipeline stages make sense for a biotech company?
- Stages that match how science actually buys: targeted lab identified, scientific conversation opened, technical evaluation or trial, procurement and budget check, and funding confirmed before close. Each stage should mark a real change in buyer commitment, not an internal task, because biotech deals move on grant timelines and reproducibility, not on quarters.
- Why are biotech sales cycles so long?
- Because buying is tied to grant and budget cycles, and the buyer is a data-driven scientist who evaluates on evidence and reproducibility before committing. A principal investigator, the end-user scientists, procurement and a grant administrator often all touch the decision, so timing the outreach to when funding and need line up matters more than pushing for speed.
- How do you forecast a biotech pipeline with long cycles?
- Weight deals by stage and overlay the funding reality: a deal is not close until the grant or budget window is confirmed. With few deals and long cycles, trends and stage conversion matter more than a precise weighted number, so track where deals stall and whether funding timing is accounted for rather than chasing a tidy forecast.
Keep reading
- CRM setup for biotech companiesHow to set up a CRM for a biotech company: fields and stages for scientific buyers, the full lab committee, grant cycles and long research-driven deals.
- Go-to-market (GTM) strategy for biotech startupsA practical GTM strategy for biotech startups: targeting the right labs, evidence-led messaging, grant-cycle timing, and the infrastructure to run it.
- How to build a sales pipeline (step by step)A step-by-step guide to building a sales pipeline for early-stage B2B startups: define stages, set entry and exit criteria, and keep it clean enough to trust.
- Sales pipeline stages for B2B, explainedWhat the stages of a B2B sales pipeline mean, with an example stage set, clear exit criteria, and how to adapt them to how your startup actually sells.
Filed under By industry. Written by Enablemnt AI.